Upexi, Inc.
$1.38+6.59%(+$0.09)
TickerSpark Score
54/100
67
Valuation
60
Profitability
55
Growth
40
Health
50
Momentum
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a UPXI research report →
52-Week Range6% of range
Low $0.54
Current $1.38
High $15.50
Companywww.upexi.com
Upexi, Inc. manufacture and sells various branded products in the health, wellness, pet, beauty, and other markets. The company was formerly known as Grove, Inc.
- CEO
- Allan J. Marshall
- IPO
- 2021
- Employees
- 64
- HQ
- Clearwater, FL, US
Price Chart
-86.03% · this period
Valuation
- Market Cap
- $96.61M
- P/E
- -0.39
- P/S
- 3.70
- P/B
- -1.73
- EV/EBITDA
- 6.94
- Div Yield
- 0.00%
Profitability
- Gross Margin
- 86.04%
- Op Margin
- 182.60%
- Net Margin
- -874.01%
- ROE
- -306.96%
- ROIC
- 25.00%
Growth & Income
- Revenue
- $15.81M · -39.19%
- Net Income
- $-13,684,209 · 42.16%
- EPS
- $-1.73 · 92.84%
- Op Income
- $-12,499,752
- FCF YoY
- -752.16%
Performance & Tape
- 52W High
- $15.50
- 52W Low
- $0.54
- 50D MA
- $1.21
- 200D MA
- $3.16
- Beta
- -0.29
- Avg Volume
- 5.05M
Get TickerSpark's AI analysis on UPXI
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Recent Insider Transactions
| Date | Insider | Type | Shares |
|---|---|---|---|
| Dec 23, 25 | MARSHALL ALLAN | buy | 50,000 |
| Dec 16, 25 | MARSHALL ALLAN | buy | 50,000 |
| Dec 15, 25 | MARSHALL ALLAN | buy | 100,000 |
| Oct 1, 25 | MARSHALL ALLAN | other | 1,600,000 |
| Nov 20, 25 | Salkind Gene | buy | 50,000 |
| Oct 1, 25 | Norstrud Andrew James | other | 240,000 |
| Nov 17, 25 | Salkind Gene | buy | 100,000 |
| Nov 17, 25 | Salkind Gene | buy | 100,000 |
| Jul 16, 25 | Salkind Gene | other | 150,000 |
| Jul 16, 25 | Salkind Gene | other | 50,000 |
Our UPXI Coverage
We haven't published any research on UPXI yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate UPXI Report →